GNI GROUP LTD.
Contact Us
About Us
About Us TOP
Message
Business Model
Main Products
Management Policy
Company Overview
Board of Directors
Main Group Structure
Office
Corporate governance
R&D
R&D TOP
Pipeline
Discovery Research
Research publications
Investor Relations
Investor Relations TOP
IR News
Information
IR Materials
IR Calendar
IR Email Subscription
Electronic Public Notices
Sustainability/ESG
Sustainability/ESG TOP
Sustainability Initiatives
ESG Data
Contact Us
Site Map
Privacy Policy
Terms of Use
ソーシャルメディアポリシー
Information
トップページ
Information
All
2026
2025
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2011/09/22
China SFDA Approves F647/Pirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis
2011/09/15
World Orphan Drug Congress
2011/08/26
(Added)Notice for Acquisition of Beijing Continent Pharmaceutical Co. Ltd.
2011/08/24
Notice of Increasing the Capital of Shanghai Genomics
2011/08/02
GNI Receives Patent Allowance on F351 and F647
2011/07/13
Notice for Acquisition of Beijing Continent Pharmaceutical Co. Ltd.
2011/07/13
Notice for Dissolving Term Sheet to Acquire Hengshan Pharmaceuticals Co. Ltd.
2011/07/07
GNI Group Files IND for Drug on Liver Failure
2011/05/11
ChinaBio Partnering Forum 2011
2011/04/27
The 4th Industrial Biotechnology (ibio) Conference
<
17
18
19
20
21
22
23
24
25
>